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ABSTRACT
Tumor-associated macrophages (TAM) play a controversial role in epithelial–mesenchymal transition (EMT)
and prognosis of colorectal cancer (CRC). In particular, the microlocalization, polarization and prognostic
impact of TAM in the immediate environment of invading CRC cells has not yet been established. To
address this clinically relevant question, intraepithelial (iCD68) and stromal macrophages (sCD68), M1-
macrophages (iNOS), M2-macrophages (CD163), cytokeratin-positive cancer cells (tumor buds) and
expression of the anti-phagocytic marker CD47 were investigated in primary tumors of 205 well-
characterized CRC patients. Cell-to-cell contacts between tumor buds and TAM were detected using high-
resolution digital scans. The composition of the tumor microenvironment was analyzed with
clinicopathological and molecular features. High CD68 counts predicted long term overall survival
independent of microlocalization (iCD68 p=0.0016; sCD68 p=0.03), pT, pN, pM and post-operative therapy.
CD68 inﬁltration correlated with signiﬁcantly less tumor budding (iCD68 p=0.0066; sCD68 p=0.0091) and
absence of lymph node metastasis (sCD68 p=0.0286). Cell-to-cell contact of sCD68 and invading cancer
cells was frequent and ameliorated the detrimental prognostic effect of the tumor budding phenotype.
Subgroup analysis identiﬁed long-term survival with CD47 loss and predominance of CD163C M2
macrophages (p D 0.0366). CD163C macrophages represented 40% of the total population, and positively
correlated with total CD68 macrophage numbers (r[CD68/CD163] D 0.32; p D 0.0001). Strong CD163
inﬁltration predicted lower tumor grade (p D 0.0026) and less lymph node metastasis (p D 0.0056). This
study provides direct morphological evidence of an interaction between TAM and inﬁltrating cancer cells.
The prognostic impact of TAM is modulated by phenotype, microlocalization and the expression of anti-
phagocytic markers in CRC.
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Introduction
Tumor-immune cell interaction is an important ﬁeld of
research regarding prognosis in CRC. A shift of perspective
away from the tumor alone toward an integrated analysis of
pro- and antitumoral factors has led to a new road map for the
understanding of cancer progression and the development of
novel therapeutic approaches.1 TAM assume a central role in
the modulation of the tumor microenvironment and mainte-
nance of the cancer stem cell niche and come in several differ-
ent ﬂavors2: M1 macrophages express pro-inﬂammatory
cytokines such as tumor necrosis factor-a (TNF-a), IL-1 and
IL-12 and have been assigned a high phagocytic activity and
the capability to drive a potent antitumoral Th1 response.3 M2
macrophages are characterized by expression of scavenger
receptors such as CD163 and the ability to induce Th2 T-cell
polarization and Foxp3-positive regulatory T cells.4 Further,
M2 macrophages may contribute to stromal remodeling,
immune escape, cancer progression and metastasis.5 The spe-
ciﬁc polarization of TAM may therefore skew the tumor
microenvironment toward tumor rejection (M1) or favor
immunotolerance, neoangiogenesis and stromal remodeling
(M2).6
Speciﬁc stromal gene expression signatures may render
the tumor microenvironment permissible for single cancer
cell invasion.7 In CRC, the presence of single cancer cells or
clusters of up to ﬁve cells in the tumor stroma (tumor bud-
ding) can be detected histologically and may be related to
EMT.8 This is supported by studies demonstrating the
acquisition of a highly motile and invasive phenotype and
the expression of markers related to the activation of Wnt-
signaling in tumor budding cells.89 In vitro studies have
provided further evidence of a remarkable phenotypic plas-
ticity of epithelial cancer cells in culture including the disin-
tegration of cell–cell adhesions, loss of epithelial polarity,
cytoskeletal remodeling and resolution of cell–matrix adhe-
sion.10 However, controversial data has been recently pro-
vided by genetic analyses that have assigned EMT-like gene
expression signatures in CRC to cancer associated ﬁbro-
blasts rather than invading cancer cells.7,11 Conclusive evi-
dence of EMT in primary CRC is therefore still lacking.
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For CRC patients, the presence of tumor budding is associated
with poor overall and disease-free survival, lymph node and dis-
tant metastasis and poor response to radio-chemotherapy.12,13
Importantly, tumor progression through EMT may be supported
by the tumor immunoenvironment: Transforming growth factor-
b (TGFb), produced by M2-polarized TAM can sustain tumor
initiation and progression;14 IL-11 and IL-6 emitted by cancer-
associated ﬁbroblasts and myeloid cells support CRC growth and
survival.15 A close interaction of inﬁltrating cancer cells withmac-
rophage populations is also supported indirectly by the detection
of tumor-loaded macrophages in the circulation of CRC
patients.16 However, the frequency of direct cell–cell interactions
of macrophages and invading cancer cells in the tumor microen-
vironment of CRC has not been previously investigated. In partic-
ular, the impact of macrophage polarization on the formation of
single cell invasion (tumor budding) in the tumor microenviron-
ment remains to be addressed.
The balance of pro- and anti-phagocytic factors may further
contribute to the susceptibility of cancer cells to immune-medi-
ated destruction. CD47, a protein involved in self-/non-self-dis-
crimination is broadly expressed on non-neoplastic tissues and
mediates a “don’t eat me signal” to tissue resident macrophages
and inﬁltrating monocytes.17 Loss of CD47 is frequent in epi-
thelial and hematological malignancies and has been associated
with a poor prognostic outcome.18,19 Further, CD47 has been
associated with increased migratory capability of invading CRC
cells20 and may represent a promising target for precision ther-
apy.19 This dual function makes CD47 a highly interesting bio-
marker for research in the context of the tumor budding
phenotype and macrophage-mediated immune functions.
In the current study, we investigate the microlocalization
and polarization of TAM in the tumor microenvironment of
invading cancer cells. We identify direct cell-to-cell interactions
by quantifying cellular contacts of TAM with tumor budding
cells. Further, we evaluate the relationship of TAM inﬁltration
and CD47 with clinicopathological and molecular features.
Last, we deﬁne prognostic groups of CRC patients based on
M1/M2 polarization and CD47 expression.
Results
Tumor buds assessed in the tissue microarray
The association of tumor budding counts with clinicopatholog-
ical features was tested using the tissue microarray approach. A
high budding count as determined by tissue microarray analy-
sis (Table S1) was associated with aggressive tumor features
including a higher tumor grade (p < 0.0001), more advanced
pT-stage (p D 0.0008), lymph node metastasis (p D 0.0015),
lymphatic (p D 0.0001) and venous invasion (p D 0.0007).
Patients with high budding counts per TMA spot had a signiﬁ-
cantly worse survival outcome (p D 0.0002) (Fig. 1A).
Intratumoral and stromal CD68C counts
Next, we evaluated both iCD68C and sCD68C counts per tumor
(Figs. 2A, B). More frequent iCD68C was correlated to signiﬁcantly
less tumor budding (pD 0.0066) and was more common in larger
tumors (pD 0.0528). sCD68C counts were linked to a larger tumor
diameter (p D 0.0364), signiﬁcantly less lymph node metastasis
Figure 1. Kaplan–Meier survival analysis, macrophage inﬁltrates and phenotypes. Survival curves of patients with primary CRC in correlation with (A) tumor budding, (B)
iCD68 and (C) sCD68 counts. (D) Survival of CRC patients in correlation with the frequency of cell-to-cell contacts between tumor buds and CD68C macrophages in the
tumor microenvironment. Survival curves of CRC patients with primary CRC dependent on (E) CD163C and (F) iNOSC macrophage counts.
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(p D 0.0286) and less tumor budding at the invasion front (p D
0.0091) (Table 1). Patients with elevated sCD68 counts less fre-
quently received post-operative therapy (p D 0.0008). Higher
counts of both iCD68 (p D 0.0016) and sCD68 (p D 0.03) were
associated with an improved overall survival time (Figs. 1B, C).
Moreover, both iCD68 and sCD68 maintained their prognostic
effect even after adjustment for pT, pN, pM and post-operative
therapy (Table 2). In order to verify the robustness of the CD68
data by visual counting, all TMA slides were digitally analyzed
using quantiﬁcation software. Results are found in (Fig. S1). Excel-
lent correlations were found between CD68 counting by eye and
by software. Performance was similar for spots on TMA slide 1
(nD 317, rD 0.86) and on TMA slides 2–3 (nD 371, rD 0.88).
Contact between tumor buds and CD68Cmacrophages
We observed direct cell-to-cell contacts between CD68C macro-
phages and tumor buds in 63/201 (31%) of the cases evaluated
(Fig. 2C). Frequent contact between buds and CD68C cells was
found in tumors with higher grade (p D 0.0307), and lymph node
metastasis (p D 0.0341), as well as in post-operatively untreated
patients (pD 0.039), MMR-deﬁcient cancers (pD 0.014) and those
with BRAF mutations (pD 0.0109) (Table 3). There was no impact
on survival (Fig. 1D), suggesting a tempering of tumor aggression
when direct contact between buds and CD68Cmacrophages occurs.
In addition, an engulfment of cancer cell fragments was frequently
seen in 97.1% of cases using pan-cytokeratin and CD68C double
immunohistochemistry (Fig. 2D) but did not show an impact on
clinicopathological features or survival.
Predominant macrophage phenotype in colorectal cancers
We next assessed CD163C and iNOSC/MCT¡ macrophages in
the tumor microenvironment. Figure 2 E-I shows immunohis-
tochemistry stains for each marker as well as a combined
CD163C/iNOSC double staining, highlighting the minimal
overlap between the two macrophage populations. The ratio of
CD163C to CD68C indicates that 40% of all CD68C macro-
phages were CD163C, whereas 60% were iNOSC (p D 0.0019).
Of note, iNOS expression was also noted in CRC cells
(Figs. 2 G-I) conﬁrming previous observations.21
Case-by-case analysis showed that there was a signiﬁcant positive
correlation between sCD68C and CD163 (r D 0.32,
p D 0.0001) but not between sCD68C and iNOS (r D ¡0.05).
Figure 2. Representative images of macrophage inﬁltrates in the colorectal microenvironment (A) Intraepithelial and (B) stromal CD68C macrophages (x100 each) (C)
Direct cell-to-cell contacts between CD68C macrophages and cytokeratin-positive tumor buds (x400) (D) Engulfment of cancer cells, as seen with pan-cytokeratin and
CD68C double immunohistochemistry (x400) (E) CD163C M2 macrophage inﬁltrates (x100) (F) iNOS (brown) / MCT (red) double stain highlighting iNOSC/MCT¡ M1 mac-
rophages (x100) (G) iNOS (brown) / CD163 (red) double stain showing co-existence of M1- and M2- polarized macrophages (x300) (H) Representative images from a tumor
with a CD163C (red) dominant M2-macrophage inﬁltrate and (I) from a tumor with an iNOSC (brown) M1-macrophage inﬁltrate (CD163/iNOS double stain; x300).
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Moreover, high CD163C counts were associated with lower tumor
grade (p D 0.0026), signiﬁcantly less lymph node metastasis (p D
0.0056), and showed a trend toward less advanced pT-stage (p D
0.0641) and absence of lymphatic invasion (p D 0.0697). Patients
with high CD163C counts were less likely to require post-operative
therapy (pD 0.0569) (Table 3). High CD163C counts were linked
to a KRAS wild-type genotype (pD 0.0068). Although not signiﬁ-
cant, a survival beneﬁt can be seen from the Kaplan–Meier curve in
Fig. 2E-F (pD 0.111) in patients with highCD163C, but not iNOS.
CD47 on overall survival and correlation with
macrophages in the tumor microenvironment
Table 4 underlines data from 183 patients with evaluable
expression for CD47 positive tumor cells. CD47 was expressed
at high levels in 47% of cases under study (Fig. S2). Indeed, a
signiﬁcantly more frequent venous invasion (p D 0.0064) and
tumor budding at the invasion front (p D 0.0491) is observed
in patients with high CD47 expression. Although not reaching
signiﬁcance, distant metastatic disease (p D 0.0822) and lym-
phatic vessel invasion (p D 0.0868) were more common in
CD47-expressing cancers.
Table 1. Association of intratumoral (i) and stromal (s) CD68C cells (normalized by stroma per punch) with clinicopathological and molecular features of CRC (n D 201).
Feature Total Freq (%) iCD68/TMA spot p value sCD68/TMA spot p value
Low High Low High
n D 163 n D 38 n D 125 n D 76
Sex Male 96 (47.8) 78 (47.9) 18 (47.4) 0.9571 59 (47.2) 37 (48.7) 0.8381
Female 105 (52.2) 85 (52.1) 20 (52.6) 66 (52.8) 39 (51.3)
Patient age (years) Mean § SD 68.2 § 11.5 68.7 § 10.9 65.7 § 13.9 0.5577 68.23 § 10.8 67.9§ 12.6 0.8348
Tumor size (cm) Mean § SD 4.5 § 2.0 4.3 § 1.9 5.1 § 2.2 0.0528 4.3 § 1.9 4.8 § 1.9 0.0364
Histological type Non-mucinous 181 (90.1) 145 (89.5) 36 (92.3) 0.5998 110 (88.7) 71 (92.2) 0.4206
Mucinous 20 (9.9) 17 (10.5) 3 (7.7) 14 (11.3) 6 (7.8)
Tumor grade G1-2 132 (65.7) 107 (66.0) 25 (64.1) 0.8182 81 (65.3) 51 (66.2) 0.8948
G3 69 (34.3) 55 (34.0) 14 (35.9) 43 (34.7) 26 (33.8)
Tumor location Left 120 (59.7) 94 (58.0) 26 (66.7) 0.4477 71 (57.3) 49 (63.6)
Rectum 27 (13.4) 24 (14.8) 3 (7.7) 20 (16.1) 7 (9.1) 0.3529
Right 54 (26.9) 44 (27.2) 10 (25.6) 33 (26.6) 21 (27.3)
pT pT1-2 53 (26.4) 40 (24.7) 13 (33.3) 0.2715 29 (23.4) 24 (31.2) 0.2235
pT3-4 148 (73.6) 122 (75.3) 26 (66.7) 95 (76.6) 53 (68.8)
pN pN0 103 (51.2) 80 (49.4) 23 (59.0) 0.282 56 (45.2) 47 (61.0) 0.0286
pN1-2 98 (48.8) 82 (50.6) 16 (41.0) 68 (54.8) 30 (39.0)
pM pM0 181 (89.6) 145 (89.0) 36 (92.3) 0.538 110 (88.0) 71 (92.2) 0.3413
pM1 21 (10.4) 18 (11.0) 3 (7.7) 15 (12.0) 6 (7.8)
L classiﬁcation L0 125 (61.6) 101 (61.6) 24 (61.5) 0.9957 74 (58.7) 51 (66.2) 0.2862
L1-2 78 (38.4) 63 (38.4) 15 (38.5) 52 (41.3) 26 (33.8)
V classiﬁcation V0 168 (82.4) 135 (82.3) 33 (82.5) 0.9783 102 (80.9) 66 (84.6) 0.5048
V1-2 36 (17.7) 29 (17.7) 7 (17.5) 24 (19.1) 12 (15.4)
Budding (10-in-10) Low-grade 114 (55.9) 84 (51.2) 30 (75.0) 0.0066 62 (48.8) 52 (67.5) 0.0091
High-grade 90 (44.1) 80 (48.8) 10 (25.0) 65 (51.2) 25 (32.5)
Therapy None 76 (37.4) 59 (36.0) 17 (43.6) 0.3772 36 (28.6) 40 (52.0) 0.0008
Post-operative 127 (62.6) 105 (64.0) 22 (56.4) 90 (71.4) 37 (48.1)
MMR status Proﬁcient 190 (93.6) 155 (95.1) 35 (87.5) 0.0788 119 (95.2) 71 (91.0) 0.2373
Deﬁcient 13 (6.4) 8 (4.9) 5 (12.5) 6 (4.8) 7 (9.0)
KRAS status Wild-type 134 (66.7) 110 (68.3) 24 (60.0) 0.3176 80 (64.5) 54 (70.0) 0.4118
Mutant 67 (33.3) 51 (31.7) 16 (40.0) 44 (35.5) 23 (30.0)
BRAF Wild-type 177 (91.2) 143 (91.1) 34 (91.9) 0.8756 112 (93.3) 65 (87.8) 0.1885
Mutant 17 (8.8) 14 (8.9) 3 (8.1) 8 (6.7) 9 (12.2)
Table 2. Multivariable Cox regression analysis of iCD68 and sCD68 counts in CRC
adjusting for pT, pN, pM and post-operative therapy.
Feature HR(95% CI) p value
iCD68 0.53 (0.29–0.95) 0.034
pT 1.61 (0.71–3.66) 0.253
pN 3.1 (1.6–6.0) 0.001
pM 3.46 (1.9–6.2) 0.000
Post-operative therapy 0.65 (0.34–1.15) 0.138
sCD68 0.6 (0.36–0.99) 0.047
pT 1.62 (0.71–3.7) 0.251
pN 2.89 (1.49–5.61) 0.002
pM 4.08 (2.27–7.32) 0.000
Post-operative therapy 0.66 (0.37–1.17) 0.154
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In univariate analysis, no association between CD47 and
overall survival could be seen (Fig. 3A). However, an effect mod-
iﬁcation by CD163 was observed. Namely, in tumors with a high
CD163C count only, CD47 expression had a major unfavorable
effect on overall survival (p D 0.0366, Fig. 3B). In contrast,
patients with a CD47 negative tumor in a CD163C and sCD68C
microenvironment had an excellent prognosis (Fig. 3C).
Discussion
Macrophages assume a controversial role in the tumor micro-
environment as both pro- and antitumoral effects have been
described. The present study investigated TAM microlocaliza-
tion, polarization and expression of the anti-phagocytic mole-
cule CD47 in the immediate environment of invading cancer
cells. Based on a comprehensive histopathological analysis, we
identify novel factors that may contribute to the differential
prognostic impact of TAMs in CRC.
First, we investigated the microlocalization of CD68C mac-
rophages in the tumor microenvironment of CRC with a spe-
cial focus on cellular contacts with inﬁltrating cancer cells.
Strong sCD68 inﬁltration was correlated with favorable clinico-
pathological features including less lymph node metastasis and
less tumor budding at the invasion front. Independently of
microlocalization in the tumor stroma or cancer epithelium,
higher counts of intratumoral macrophages were associated
with an improved overall survival time. This data corroborates
prognostic analyses on the favorable impact of overall CD68C
counts in CRC patients.22,23 Interesting, however, is the absence
of statistically signiﬁcant differences for most of the prognostic
factors associated with tumor budding in cases with strong
cell–cell contact between macrophages and inﬁltrating cancer
cells. This implies that macrophages may directly or indirectly
counter cancer cell invasion in the tumor stroma. Indeed, For-
ssell and colleagues previously demonstrated that cellular con-
tact between macrophages and tumor cells may inhibit cancer
cell proliferation using functional assays but did not conﬁrm
the co-localization of TAM with invading cancer cells in the
tumor microenvironment of CRC resection specimens.22 In
support of the in vitro observations, we now detected frequent
cellular contacts between macrophages and inﬁltrating cancer
cells in the stromal compartment. Further evidence for a close
Table 3. Association of CD68C buds contact, stromal CD163 and iNOS (normalized by percent stroma per TMA spot) with clinicopathological features.
Feature
Contact CD68C buds/TMA
spot (n D 201) p value
CD163/TMA spot
(n D 137) p value
iNOS/TMA spot
(n D 137) p value
Low High Low High Low High
n D 138 n D 63 n D 84 n D 53 n D 82 nD 55
Sex Male 66 (47.8) 30 (47.6) 0.9783 39 (46.4) 26 (49.1) 0.7642 40 (48.8) 26 (47.3) 0.8625
Female 72 (52.2) 33 (52.4) 4 (53.6) 27 (50.9) 42 (51.2) 29 (52.7)
Patient age (years) Mean § SD 68.3§12.2 67.7§9.9 0.3374 66.3§11.4 70.2§11.0 0.186 68.7§10.9 69.8§11.9 0.4533
Tumor size (cm) Mean § SD 4.6§1.9 4.2§1.9 0.2731 4.3§1.8 4.5§2.0 0.4348 4.7§2.0 4.2§1.8 0.1524
Histological
subtype
Non-mucinous 126 (90.7) 55 (88.7) 0.6716 74 (88.1) 51 (96.2) 0.1011 70 (85.4) 54 (98.2) 0.0121
Mucinous 13 (9.4) 7 (11.3) 10 (11.9) 2 (3.8) 12 (14.6) 1 (1.8)
Tumor grade G1-2 98 (70.5) 34 (54.8) 0.0307 51 (60.7) 45 (84.9) 0.0026 53 (64.6) 40 (72.7) 0.32
G3 41 (29.5) 28 (45.2) 33 (39.3) 8 (15.1) 29 (35.4) 15 (27.3)
Tumor location Left 84 (60.9) 36 (57.1) 47 (56.0) 34 (64.2) 52 (63.4) 30 (54.6)
Rectum 19 (13.8) 8 (12.7) 0.7757 9 (10.7) 7 (13.2) 0.4036 7 (8.5) 11 (20.0) 0.149
Right 35 (25.4) 19 (30.2) 28 (33.3) 12 (22.6) 23 (28.1) 14 (25.5)
pT pT1-2 39 (28.1) 14 (22.6) 0.4157 18 (21.4) 19 (35.9) 0.0641 19 (23.2) 18 (32.7) 0.2169
pT3-4 100 (71.9) 48 (77.4) 66 (78.6) 34 (64.2) 63 (76.8) 37 (67.3)
pN pN0 75 (54.0) 28 (45.2) 0.2492 40 (47.6) 38 (71.7) 0.0056 45 (54.9) 33 (60.0) 0.5529
pN1-2 64 (46.0) 34 (54.8) 44 (52.4) 15 (28.3) 37 (45.1) 22 (40.0)
pM pM0 125 (89.9) 56 (88.9) 0.8226 73 (86.9) 47 (88.7) 0.759 73 (89.0) 46 (83.6) 0.3601
pM1 14 (10.1) 7 (11.1) 11 (13.1) 6 (11.3) 9 (11.0) 9 (16.4)
Lymphatic invasion L0 93 (66.4) 32 (50.8) 0.0341 49 (58.3) 39 (73.6) 0.0697 49 (59.8) 39 (70.9) 0.1819
L1-2 47 (33.6) 31 (49.2) 35 (41.7) 14 (26.4) 33 (40.2) 16 (29.1)
Vascular invasion V0 118 (83.7) 50 (79.4) 0.4543 66 (78.6) 47 (87.0) 0.2076 67 (81.7) 43 (78.2) 0.6111
V1-2 23 (16.3) 13 (20.6) 18 (21.4) 7 (13.0) 15 (18.3) 12 (21.8)
Budding (10-in-10) Low-grade 94 (66.7) 20 (31.8) <0.0001 45 (53.6) 34 (63.0) 0.2764 47 (57.3) 30 (53.6) 0.6635
High-grade 47 (33.3) 43 (68.3) 39 (46.4) 20 (37.0) 35 (42.7) 26 (46.4)
Therapy None 59 (42.1) 17 (27.0) 0.039 29 (34.5) 27 (50.9) 0.0569 30 (36.6) 25 (45.5) 0.2992
Post-operative 81 (57.9) 46 (73.0) 55 (65.5) 26 (49.1) 52 (63.4) 30 (54.5)
MMR status Proﬁcient 135 (96.4) 55 (87.3) 0.014 76 (91.6) 49 (90.7) 0.8674 77 (95.1) 49 (89.1) 0.1904
Deﬁcient 5 (3.6) 8 (12.7) 7 (8.4) 5 (9.3) 4 (4.9) 6 (10.9)
KRAS status Wild-type 94 (67.6) 40 (64.5) 0.6658 47 (56.6) 42 (79.3) 0.0068 52 (64.2) 38 (69.1) 0.5539
Mutant 45 (32.4) 22 (35.5) 36 (43.4) 11 (20.8) 29 (35.8) 17 (30.9)
BRAF Wild-type 126 (94.7) 51 (83.6) 0.0109 74 (91.4) 46 (88.5) 0.5831 74 (91.4) 45 (88.2) 0.5577
Mutant 7 (5.3) 10 (16.4) 7 (8.6) 6 (11.5) 7 (8.6) 6 (11.8)
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interaction of TAM with invading cancer cells is provided by
the detection of tumor loaded macrophages in the tumor
microenvironment16 and in blood samples24 of CRC patients.
However, neither co-localization nor phagocytic uptake of
tumor cell fragments provides further insight into mechanistic
interaction. Validation of these observations in experimental
studies is therefore recommended.
Second, we addressed the correlation of macrophage polari-
zation with the tumor budding phenotype. We veriﬁed the
mutual exclusivity of distinct CD163C and iNOS positive popu-
lations using immunohistochemical double stains. For evalua-
tion of M1 macrophages, a double staining technique using
mast cell tryptase and iNOS was used. This was found to be
highly beneﬁcial for excluding iNOS-positive mast cells from
analysis. Previous studies using iNOS as a marker have so far
failed to take the potential contribution of mast cells to the
iNOS-positive population into account.25 This may explain
why some divergent results have been published regarding the
frequency and clinicopathological impact of the M1 and M2
phenotype in CRC. Interestingly, iNOSC and CD163C counts
were strongly correlated in the tumor microenvironment, pro-
viding further evidence that TAM form a heterogeneous popu-
lation that may change during tumor progression.26
Importantly, iNOS-positive macrophage counts did not show
an impact on clinicopathological features or survival in the
present study. Instead, the positive associations of CD68C
inﬁltrates with favorable clinicopathological characteristics
seem to be primarily driven by the presence of CD163C mac-
rophages. This counterintuitive ﬁnding is consistent with
several published studies that have described a tendency
Table 4. Association of CD47 expression with clinicopathological and molecular features (n D 182).
Feature CD47 freq (%) p value
Low High
n D 96 n D 86
Sex Male 51 (53.1) 35 (41.2) 0.1082
Female 45 (46.9) 50 (58.8)
Patient age (years) Mean § SD 69.3§11.8 68.0§11.0 0.4164
Tumor size (cm) Mean § SD 4.5§2.1 4.5§1.8 0.6153
Histological subtype Non-mucinous 90 (93.8) 75 (87.2) 0.1301
Mucinous 6 (6.3) 11 (12.8)
Tumor grade G1-2 68 (70.8) 52 (60.5) 0.1406
G3 28 (29.2) 34 (39.5)
Tumor location Left 51 (53.7) 55 (64.0) 0.3028
Rectum 16 (16.8) 9 (10.5)
Right 28 (29.5) 22 (25.6)
pT pT1-2 29 (30.2) 19 (22.1) 0.2148
pT3-4 67 (69.8) 67 (77.9)
pN pN0 55 (57.3) 40 (46.5) 0.1461
pN1-2 41 (42.7) 46 (53.5)
pM pM0 90 (93.8) 74 (86.1) 0.0822
pM1 6 (6.3) 12 (14.0)
Lymphatic invasion L0 65 (67.0) 47 (54.7) 0.0868
L1-2 32 (33.3) 39 (45.4)
Vascular invasion V0 88 (90.7) 66 (75.9) 0.0064
V1-2 9 (9.3) 21 (24.1)
Budding (10-in-10) Low-grade 57 (59.4) 39 (44.8) 0.0491
High-grade 39 (40.6) 48 (55.2)
Therapy None 38 (39.2) 33 (38.4) 0.9114
Post-operative 59 (60.8) 53 (61.6)
MMR status Proﬁcient 90 (92.8) 81 (94.2) 0.7021
Deﬁcient 7 (7.2) 5 (5.8)
KRAS status Wild-type 58 (60.4) 61 (70.9) 0.1366
Mutant 38 (39.6) 25 (29.1)
BRAF Wild-type 85 (92.4) 76 (90.5) 0.6495
Mutant 7 (7.6) 8 (9.5)
iNOS Low 36 39 0.586
High 27 24
CD163 Low 39 38 0.637
High 28 23
sCD68 Low 57 55 0.536
High 40 32
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toward more favorable outcome of CRC patients with
increasing counts of M2 macrophages in the tumor microen-
vironment.23,27 Based on mechanistic data, macrophage phe-
notypes may be highly plastic and modulated by pro-
inﬂammatory cytokines26 and secreted factors from invading
cancer cells.28 As with regulatory T cells, the speciﬁc context,
temporal kinetics and organ type may inﬂuence the prognos-
tic impact of macrophage inﬁltrates in the immunoenviron-
ment of solid tumors.29 Mechanistic studies seem required to
address the prognostic impact of TAM in CRC in the context
of these variables. Further, a relatively low percentage of
MMR-deﬁcient tumors were detected in the present cohort
(6.4%), which may limit the application of the present results
to tumors with this molecular phenotype. We therefore rec-
ommend independent validation of the present data in CRC-
patients with MMR-deﬁciency.
Last, we addressed the impact of the anti-phagocytic “don’t eat
me” molecule CD47 on macrophage populations, polarization and
prognosis of CRC patients. As both tumor-related and host-related
factors inﬂuence the prognosis of CRC patients, an integrative
approach toward microenvironment studies may better capture the
biological aggressiveness of CRC on a case-by-case basis. Based on
the anti-phagocytic function of CD47, we hypothesized that tumors
with an elevated CD47 expression would display decreased macro-
phage inﬁltration and an aggressive phenotype. In agreement with
this, venous invasion and high grade tumor budding was frequently
observed in CD47high tumors. Interestingly, CD47 expression also
signiﬁcantly modiﬁed the prognostic impact of TAM inﬁltration. In
tumors with strong CD163 inﬁltration, CD47 expression had a
major negative effect on survival, indicating that CD47C tumor cells
may be more resistant toward antitumoral effector mechanisms in a
macrophage-rich tumormicroenvironment [Fig. 4].
Figure 4. Working model.
Figure 3. Kaplan–Meier survival analysis, CD47 expression. (A) Survival curves of patients with primary CRC in correlation with high or low CD47 expression. (B) Subgroup
analysis of CD47 expression in tumors with strong CD163C macrophage inﬁltration. (C) Subgroup analysis of patients with CD47 negative tumors and strong macrophage
inﬁltration in comparison to all other marker combinations.
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Conclusions
In summary, our results suggest a direct interaction of inﬁltrat-
ing cancer cells with TAM. Cellular contact and engulfment of
tumor cell fragments is frequent in the microenvironment of
CRC. Strong macrophage inﬁltration is an independent favor-
able prognostic indicator for CRC patients and may counter
the aggressive tumor budding phenotype. This favorable prog-
nostic impact of CD68C inﬁltrates is maintained independent
of macrophage polarization but is strongly modiﬁed by the
expression of the anti-phagocytic molecule CD47 on colorectal
tumors. Further experimental studies are recommended to
decipher the mechanistic interaction of TAM with inﬁltrating
cancer cells in the immunoenvironment.
Materials and methods
Patient cohort
Two hundred and one patients with primary CRC were entered
into this study (Fig. S3). Patients were treated at the Fourth
Department of Surgery, University of Athens, Greece between
2002 and 2007. Full histopathological re-review of tumor grade,
histological subtype, pT, pN, pM, V and L classiﬁcations was
conducted according to the TNM Classiﬁcation of Malignant
Tumors, 7th Edition (2009).30 The total number of tumor buds
in each TMA spot (diameter 0.6 mm) was counted using pan-
cytokeratin stains.31,32 The primary endpoint of interest was
overall survival. Other clinical data retrieved from patient
charts included age, tumor size, gender and post-operative
therapy. No patients received any neoadjuvant treatment.
Patient characteristics can be found in Table 1. This study was
designed in accordance with the REMARK criteria.33
Next-generation Tissue Microarray (ngTMA) construction
Tissue microarrays were constructed using the ngTMA
approach.34 For each patient, one hematoxylin and eosin
(H&E) stained whole tissue slide containing representative
regions of tumor center and invasion front was scanned (Pan-
noramic P250, 3DHistech, Budapest, Hungary). Using a tissue
microarray annotation tool of 0.6 mm in diameter, slides were
digitally annotated as follows: three regions of tumor center
(blue); three regions of invasion front (yellow) and two regions
of densest tumor budding (red), if available (Fig. S4).35 Next,
corresponding formalin-ﬁxed (10% buffered formalin) paraf-
ﬁn-embedded tissue blocks were loaded into an automated tis-
sue microarrayer (TMA Grandmaster, 3DHistech, Budapest,
Hungary). The digital slides were aligned with the correspond-
ing donor block. Annotated regions were cored from the donor
block and transferred to the recipient ngTMA. Five different
ngTMA blocks were produced resulting in 1608 spots for
evaluation.
Immunohistochemistry
ngTMAs were sectioned at 3 mm. Immunohistochemistry was
performed on an automated platform (Leica Bond RX, Leica
Biosystems, Muttenz, Switzerland). Single immunohistochem-
istry for pan-cytokeratin, CD47, CD68, CD163 and iNOS were
performed in addition to a double-immunohistochemistry for
CD163 and iNOS, CD163 and CD68, iNOS and CD68, and
iNOS and mast cell tryptase (MCT). iNOS/MCT double stains
were used to support the differentiation of iNOSC/MCTC mast
cells from iNOSC/MCT¡M1 macrophages. Details on antibod-
ies and conditions are found in Table S2.
Normalization and scoring
Since each patient had multiple tumor cores taken from differ-
ent regions within the tumor, the percentage of positive tumor
cells across all cores was averaged. Both intraepithelial (i) and
stromal (s) CD68C macrophage counts were assessed. Cell–cell
contacts between CD68C macrophages and pancytokeratin-
positive tumor budding cells in the stroma were quantiﬁed on
high resolution digital scans (400x) using strict criteria: Cellular
integrity, an identiﬁable nucleus and complete cytoplasmic
(pancytokeratin, tumor buds) or membranous immunoreactiv-
ity (CD68) of each cell was required. A direct cell–cell linkage
spanning at least one third of the cellular circumference was
required to qualify for cellular contact between a tumor bud
and stromal macrophages. For CD163 and iNOS, stromal inﬁl-
trates were counted on a numerical scale. Since a single tissue
microarray spot may contain various degrees of stroma vs.
tumor epithelial content, the percentage of stroma and tumor
tissue per spot was recorded. Cell counts were normalized for
tumor cell and stromal content of each spot. CD47 expression
was scored by visual estimate as the percentage of tumor cells
showing membranous reactivity in each spot; visual estimates
were rounded to the nearest 5% and averaged for each case.
Robustness of quantiﬁcation procedures was assured by scoring
of a subset of cases for each marker and marker combination
by two independent observers (VHK and KC) in training ses-
sions using a test TMA of 50 CRC cases. Disagreement was
resolved using a multi-headed microscope preceding the appli-
cation of the scoring combinations on the deﬁnite cohort. As
CD68 was identiﬁed as an independent prognostic marker,
inter-observer agreement was additionally assessed using
HALO image analysis software (Indica Labs, Albuquerque,
NM, USA) focusing on tumor spots (n D 688) distributed
across three TMA slides. The algorithm was developed on slide
1 and applied to all three TMA slides (Fig. S1).
Assessment of KRAS, BRAF mutations and MMR status
BRAF (exon 15, V600E mutations) and KRAS (exon 2, codon
12 and 13) mutations were detected by pyrosequencing.36
MMR status was based on expression of MLH1, MSH2, MSH6
and PMS2 by immunohistochemistry. Patients were considered
MMR deﬁcient when at least one protein was completely
negative.
Statistical analysis
Spearman correlation coefﬁcients (r) were used to determine
the strength of the relationship between CD47, iCD68, sCD68,
CD163 and iNOS. For consistency, scores were then dichoto-
mized according to the mean into low and high groups. The
Chi-Square test was used to determine the association of low
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and high cell counts with categorical variables and t-test for
tumor size and age. Kaplan–Meier survival curves were plotted
and survival time differences analyzed using the log-rank test.
Multivariable Cox regression analysis was performed in order
to determine the independent prognostic effect of the feature
after adjustment for potential confounders. The proportional
hazards assumption was veriﬁed. Hazard Ratios (HR) and 95%
CI were used to determine effect size. Pearson’s correlation
coefﬁcient was used to evaluate the strength of linear relation-
ship between CD68 counts by a human observer and by soft-
ware. All p values were two sided and considered signiﬁcant
when p < 0.05. Analyses were conducted on SPSS (V21) and
SAS (V9.3, Cary, NC).
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